Optimi signs international natural psilocybin supply agreement with New Zealand-Based Mātai Medical Research Institute, on behalf of the Tū Wairua Project.
NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd (Nasdaq:PBM) (Psyence Biomed or the Company) today announced that its Australian subsidiary, Psyence Australia Pty Ltd....
Optimi receives Certificate Of Analysis for GMP Natural Psilocybin Extract. Company has also completed the in-house encapsulation of 5mg & 10mg psilocybin.
TORONTO, April 02, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (Revive or the Company) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research...
Rose Hill Leads the Way in Psilocybin Production
Incannex Announces Positive Results from Phase 2 Psi-GAD1 Trial of Psilocybin
Psychedelics-focused biotech Compass Pathways has signed a research collaboration with New Jersey’s Hackensack Meridian Health regarding the delivery model design of its investigational COMP360 psilocybin treatment.
LONDON, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (œCompass), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental...
Terran Biosciences Receives Notice of Allowance for Four US Patents
LONDON, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (œCompass), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental...